Christopher Richard Anzalone Sells 13,445 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 13,445 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $67.66, for a total transaction of $909,688.70. Following the sale, the chief executive officer owned 3,818,512 shares in the company, valued at $258,360,521.92. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Monday, December 22nd, Christopher Richard Anzalone sold 12,586 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.44, for a total transaction of $861,385.84.
• On Wednesday, December 17th, Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $64.04, for a total transaction of $5,443,400.00.
• On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $62.58, for a total transaction of $3,397,968.84.
• On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.85, for a total value of $8,950,500.00.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $70.50 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $72.36. The stock has a market cap of $9.58 billion, a P/E ratio of -881.13 and a beta of 1.28. The stock’s 50 day simple moving average is $50.46 and its 200 day simple moving average is $32.32. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Company-scheduled investor activity in early January could be a near-term catalyst: a KOL webinar on Jan 6 that will present interim clinical data for obesity programs ARO‑INHBE and ARO‑ALK7, and a corporate presentation at the J.P. Morgan Healthcare Conference the week of Jan 12. Positive interim data or a well-received JPM presentation could lift sentiment. Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
• Positive Sentiment: Analysts have been raising targets in December (multiple banks increased price objectives and reiterated buy/outperform views), which supports positive investor sentiment and can underpin higher trading levels heading into data/events.
• Neutral Sentiment: Short-interest reporting in late December shows anomalous/zero values in the public feed (appears to be a data error), so short-interest signals are currently unreliable for gauging downside pressure. Investors should watch for corrected exchange reports.
• Negative Sentiment: Multiple insiders sold shares in late December — including CEO Christopher Anzalone and several directors — disclosed in SEC Form 4 filings. While the CEO still holds a large stake and the percentage reductions were modest, clustered insider sales can be viewed negatively by some market participants. See SEC filings for details: CEO Form 4 CEO Form 4, Director filings and trade disclosures Director Form 4 Director Form 4 and a trade summary on InsiderTrades for one director InsiderTrades Waddill Sale.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Cantor Fitzgerald L. P. grew its position in shares of Arrowhead Pharmaceuticals by 14.7% in the third quarter. Cantor Fitzgerald L. P. now owns 19,500 shares of the biotechnology company’s stock valued at $673,000 after purchasing an additional 2,500 shares during the period. CIBC Bancorp USA Inc. acquired a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth about $444,000. Keystone Financial Group purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at about $276,000. CANADA LIFE ASSURANCE Co increased its stake in shares of Arrowhead Pharmaceuticals by 11.7% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 129,958 shares of the biotechnology company’s stock valued at $4,389,000 after acquiring an additional 13,653 shares during the last quarter. Finally, Woodline Partners LP lifted its holdings in shares of Arrowhead Pharmaceuticals by 34.0% during the 3rd quarter. Woodline Partners LP now owns 1,000,158 shares of the biotechnology company’s stock worth $34,495,000 after acquiring an additional 254,002 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of research reports. Bank of America increased their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Piper Sandler raised their price objective on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. HC Wainwright increased their target price on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Finally, Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.89.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.